Dr. Kennedy on RAS as a Target

Perry Kennedy, MD, postdoctoral research fellow, H. Lee Moffitt Cancer Center and Research Institute, discusses RAS as a target as well as the NCI RAS Initiative.

Perry Kennedy, MD, postdoctoral research fellow, H. Lee Moffitt Cancer Center and Research Institute, discusses RAS as a target as well as the NCI RAS Initiative.

RAS has been thought to be a difficult therapeutic target, Kennedy explains. Since RAS has very shallow binding pockets, it is challenging for small-molecule inhibitors to bind to and attack it.

However, an exciting component of the NCI RAS Initiative, he adds, is that researchers are actively working to attack RAS from different angles, both directly and indirectly, to better understand its behavior.

Related Videos
View All
Related Content